Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1941. Mammography screening as a method for the early detection of breast cancer

Mammography screening as a method for the early detection of breast cancer Mammography screening as a method for the early detection of breast cancer Mammography screening as a method for the early detection of breast cancer Gibis B, Busse R, Reese E, Richter K, Schwartz FW, Koebberling J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Gibis B, Busse R, Reese E, Richter K, Schwartz FW, Koebberling J. Mammography screening as a method for the early detection of breast cancer. German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA@ DIMDI). 1998 Authors' objectives This report aims to answer the following questions: - To what extent are reductions in the efficacy of a mammography screening programme with a participation rate of under 70% to be tolerated? - What quality

Health Technology Assessment (HTA) Database.1998

1942. Psycho-social interventions in oncology: counselling services for women with breast cancer

Psycho-social interventions in oncology: counselling services for women with breast cancer Psycho-social interventions in oncology: counselling services for women with breast cancer Psycho-social interventions in oncology: counselling services for women with breast cancer Whatley P, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Whatley P, Milne R. Psycho-social interventions in oncology: counselling services for women with breast cancer. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998: 20 Authors' objectives To provide an overview of the value of counselling services for women with breast cancer. Authors' conclusions There is good evidence from trials that counselling helps women with breast cancer in terms of psychological adjustment in the months after diagnosis. The Committee noted

Health Technology Assessment (HTA) Database.1998

1943. Randomised controlled trial of effects of early discharge after surgery for breast cancer.

Randomised controlled trial of effects of early discharge after surgery for breast cancer. 9804712 1998 12 14 1998 12 14 2014 06 17 0959-8138 317 7168 1998 Nov 07 BMJ (Clinical research ed.) BMJ Randomised controlled trial of effects of early discharge after surgery for breast cancer. 1275-9 To determine the effect of early discharge from hospital after surgery for breast cancer on physical and psychological illness. Randomised controlled trial comparing discharge two days after surgery (before (...) removal of drain) with standard management (discharge after removal of drain). Regional breast unit. 100 women with early breast cancer undergoing mastectomy and axillary node clearance (20) or breast conservation surgery (80). Physical illness (infection, seroma formation, shoulder movement) and psychological illness (checklist of concerns, Rotterdam symptom questionnaire, hospital anxiety and depression scale) preoperatively and at one month and three months postoperatively. Women discharged early

BMJ1998 Full Text: Link to full Text with Trip Pro

1944. Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial.

Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial. 9554895 1998 05 21 1998 05 21 2014 06 17 0959-8138 316 7140 1998 Apr 25 BMJ (Clinical research ed.) BMJ Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial. 1267-71 To assess the medical and psychosocial effects of early hospital discharge after surgery for breast cancer on complication rate, patient satisfaction, and psychosocial outcomes (...) . Randomised trial comparing discharge from hospital 4 days after surgery (with drain in situ) with discharge after drain removal (mean 9 days in hospital). Psychosocial measurements performed before surgery and 1 and 4 months after. General hospital and cancer clinic in Rotterdam with a socioeconomically diverse population. 125 women with operable breast cancer. Incidence of complications after surgery for breast cancer, patient satisfaction with treatment, and psychosocial effects of short stay or long

BMJ1998 Full Text: Link to full Text with Trip Pro

1945. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. 9716055 1998 09 08 1998 09 08 2015 06 16 0140-6736 352 9127 1998 Aug 15 Lancet (London, England) Lancet Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. 515-21 Uncontrolled studies suggest that high-dose chemotherapy is beneficial (...) in patients with breast cancer and multiple metastases to the axillary lymph nodes. Many physicians accept this treatment as standard care. We aimed to assess adjuvant high-dose chemotherapy in breast cancer in a phase II randomised trial. 97 women aged younger than 60 years, who had breast cancer with extensive axillary-node metastases (confirmed by a tumour-positive infraclavicular lymph-node biopsy), received three courses of up-front chemotherapy (FE120C). This regimen consisted of cyclophosphamide

Lancet1998

1946. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. 9672273 1998 07 28 1998 07 28 2015 06 16 0140-6736 352 9122 1998 Jul 11 Lancet (London, England) Lancet Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. 93-7 Tamoxifen is a candidate chemopreventive agent in breast (...) cancer, although the drug may be associated with the development of endometrial cancer. Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive. In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy. Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years. The original plan was to follow the intervention phase

Lancet1998

1947. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. 9672274 1998 07 28 1998 07 28 2015 06 16 0140-6736 352 9122 1998 Jul 11 Lancet (London, England) Lancet Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. 98-101 Tamoxifen, a drug with antioestrogenic effects, is predicted to prevent the occurrence of breast cancer. We have undertaken a trial (...) of tamoxifen in healthy women who are at increased risk of breast cancer because of family history. We report a planned interim analysis. Between October, 1986, and April, 1996, we accrued 2494 healthy women aged between 30 and 70 with a family history of breast cancer. They have been randomised (double blind) to receive tamoxifen 20 mg per day orally or placebo for up to 8 years. Follow-up included clinical assessment, annual mammography, and assessment of toxicity and compliance. The primary endpoint

Lancet1998

1948. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

Reduction in new metastases in breast cancer with adjuvant clodronate treatment. 9691101 1998 08 06 1998 08 06 2013 11 21 0028-4793 339 6 1998 Aug 06 The New England journal of medicine N. Engl. J. Med. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. 357-63 Bisphosphonates are effective against the increased bone resorption caused by certain diseases because they inhibit the activity of osteoclasts. In patients who have breast cancer and metastatic bone disease (...) , the bisphosphonate clodronate (clodronic acid) reduces the frequency of skeletal complications. Experiments in animals and preliminary clinical observations indicate that early clodronate therapy reduces the incidence of new bony metastases in breast cancer. We investigated the effects of clodronate on the incidence and extent of new metastases in patients with breast cancer. Between 1990 and 1995, 302 patients with primary breast cancer and tumor cells in the bone marrow (the presence of which is a risk factor

NEJM1998

1949. The risk of breast cancer following spontaneous or induced abortion

The risk of breast cancer following spontaneous or induced abortion The risk of breast cancer following spontaneous or induced abortion The risk of breast cancer following spontaneous or induced abortion Wingo P A, Newsome K, Marks J S, Calle E E, Parker S L Authors' objectives To evaluate the relationship between breast cancer risk and spontaneous and induced abortion. Searching Computer-based databases and bibliographies of published articles were searched up to January 1996. Literature (...) written in any language was considered. Study selection Study designs of evaluations included in the review Cohort and case-control studies. The review included all studies that provided some data separately for women who had had spontaneous or induced abortions. Specific interventions included in the review Abortion. Participants included in the review Women who had spontaneous or induced abortion were included. Outcomes assessed in the review The risk of breast cancer was assessed. How were

DARE.1997

1950. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer (...) Crump M, Sawka C A, DeBoer G, Buchanan R B, Ingle J N, Forbes J, Meakin J W, Shelley W, Pritchard K I Authors' objectives To compare the effectiveness of tamoxifen and ovarian ablation or oophorectomy as first-line treatment in premenopausal women with metastatic breast cancer. Searching MEDLINE and Cancerlit were searched and a bibliographic review of related publications was undertaken. The principal investigators of unpublished trials were contacted directly regarding the inclusion of their data

DARE.1997

1951. Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer

Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer Clahsen P C, van de Velde C J, Goldhirsch A, Rossbach J, Sertoli M R, Bijnens L, Sylvester R J Authors' objectives The objective was to determine whether peri-operative polychemotherapy (PeCT (...) ) could prolong overall survival in women with early breast cancer. Searching MEDLINE was searched, but the dates and search terms were not reported. The authors handsearched proceedings of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the European Cancer Conference. Experts in the field were also contacted to identify trials. Data had to be received by February 1994 to be included in the review. Study selection Study designs of evaluations included

DARE.1997

1952. Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival

Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival Morris A D, Morris R D, Wilson J F, White J, Steinberg S, Okunieff P, Arriagada R, Le M G, Blichert-Toft M, van Dongen J A Authors' objectives To assess whether 10-year survival (...) in early-stage breast cancer is affected by type of surgery. Searching MEDLINE was searched from 1966 to 1995 for English language papers only. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs), comparing mastectomy with breast-conserving therapy in the treatment of early-stage breast cancer, were included. Specific interventions included in the review Mastectomy, breast-conserving therapy (BCT), with or without radiotherapy. Participants included

DARE.1997

1953. Progestatifs et metastases osseuses dans les cancers du sein [Hormonotherapy in breast cancer with bone metastasis]

Progestatifs et metastases osseuses dans les cancers du sein [Hormonotherapy in breast cancer with bone metastasis] Progestatifs et metastases osseuses dans les cancers du sein [Hormonotherapy in breast cancer with bone metastasis] Progestatifs et metastases osseuses dans les cancers du sein [Hormonotherapy in breast cancer with bone metastasis] Leriche N, Bonneterre J Authors' objectives To investigate the efficacy of progestogens compared with other hormone therapies in women with breast (...) with alternative progestogens or hormone antagonists (tamoxifen 20-40 mg/day; aminoglutethimide 250-500 mg/day with hydrocortisone 40-50 mg/day). Participants included in the review Breast cancer patients with bone metastases (measurable and/or evaluable) were included. Neither menopausal status nor level of hormonal receptors was a selection criterion. Outcomes assessed in the review Bone lesions were assessed by skeletal x-ray or bone scans every three months or after six weeks of treatment. Response

DARE.1997

1954. Economic evaluation of a mammography-based breast cancer screening programme in Spain

Economic evaluation of a mammography-based breast cancer screening programme in Spain Economic evaluation of a mammography-based breast cancer screening programme in Spain Economic evaluation of a mammography-based breast cancer screening programme in Spain Garuz R, Forcen T, Cabases J, Antonanzas F, Trinxet C, Rovira J, Anton F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A mammography-based breast cancer screening programme. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised women between 50 and 65 years of age. Setting Secondary care. The study was carried out in Spain. Dates to which data relate The data for the effectiveness

NHS Economic Evaluation Database.1997

1955. Image-guided core biopsy has advantages over needle localization biopsy for the diagnosis of nonpalpable breast cancer

Image-guided core biopsy has advantages over needle localization biopsy for the diagnosis of nonpalpable breast cancer Image-guided core biopsy has advantages over needle localization biopsy for the diagnosis of nonpalpable breast cancer Image-guided core biopsy has advantages over needle localization biopsy for the diagnosis of nonpalpable breast cancer Whitten T M, Wallace T W, Bird R E, Turk P S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) and subsequently diagnosed with breast cancer. Setting Secondary care. The economic study was performed in the USA. Dates to which data relate Effectiveness data were collected during the period January 1994 and December 1995. The price year was not stated. Source of effectiveness data The evidence for outcomes was derived from a single study. Link between effectiveness and cost data The costing was undertaken retrospectively on the same patient sample as that used in the effectiveness study. Study sample

NHS Economic Evaluation Database.1997

1956. Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy

Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy Kwon A H, Yamada O, Uetsuji S, Matsui Y, Kamiyama Y Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prophylactic laparoscopic ovarian oophorectomy for premenopausal breast cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with breast cancer with positive estrogen receptor (ER) and with clinical stage of breast cancer greater than stage IIB

NHS Economic Evaluation Database.1997

1957. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I: results from a randomized trial

The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I: results from a randomized trial The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I: results from a randomized trial The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I: results from a randomized (...) trial Liljegren G, Karlsson G, Bergh J, Holmberg L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Type of intervention

NHS Economic Evaluation Database.1997

1958. [A medico-economic analysis of second line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine]

[A medico-economic analysis of second line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine] Evaluation medico-economique de la chimiotherapie de 2e ligne dans le cancer du sein metastatique: comparaison du docetaxel, du paclitaxel et de la vinorelbine [A medico-economic analysis of second line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine] Evaluation medico-economique de la chimiotherapie de 2e ligne dans le (...) cancer du sein metastatique: comparaison du docetaxel, du paclitaxel et de la vinorelbine [A medico-economic analysis of second line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine] Launois R J, Reboul-Marty J M, Bonneterre J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

NHS Economic Evaluation Database.1997

1959. The economic impact of technical change in the local treatment of breast cancer

The economic impact of technical change in the local treatment of breast cancer The economic impact of technical change in the local treatment of breast cancer The economic impact of technical change in the local treatment of breast cancer Kurdas C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Breast-conserving treatment of breast cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Women with breast cancer. Setting Secondary care. The economic study was carried out in the United States. Dates to which data relate The dates of the effectiveness data were not reported. The resource use data were based on 1991 breast cancer incidence, but the dates of other model assumptions

NHS Economic Evaluation Database.1997

1960. Breast cancer

Breast cancer Breast cancer Breast cancer Scottish Health Purchasing Information Centre Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Scottish Health Purchasing Information Centre. Breast cancer. Aberdeen: Scottish Health Purchasing Information Centre (...) (SHPIC) 1997 Authors' objectives This report looks at surgery, radiotherapy, hormone therapy, chemotherapy drugs to prevent or reduce nausea and vomiting after chemotherapy, follow-up after surgery and adjuvant treatment, and breast cancer nurses. Authors' conclusions 1. Surgery - the choice between mastectomy and breast conservation depends on tumour factors and patient preference; cost is not a factor in that choice. 2. Radiotherapy is effective and cost-effective in reducing local recurrence after

Health Technology Assessment (HTA) Database.1997